Lucideon, the international materials technology company, along with its partners on the ReBioStent project, will be hosting a satellite session, “Bioresorbable Materials for Medical Applications,” at the European Society of Biomaterials (ESB) conference 2015 in Krakow, Poland on the September 2, 2015.
The session will focus on the latest research, development and commercialization of bioresorbable materials and products and provide insight into the ReBioStent project which has been running since January 2014.
ReBioStent is an EU funded project on innovative bioresorbable drug-eluting stents. Lucideon and its 13 partners from industry and academia are developing novel materials and products which can be drug loaded, offer improved mechanical properties to the products currently on the market and can be absorbed safely into the body once their function is complete.
“The session in Krakow will allow us and our partners on ReBioStent to provide an insight into bioresorbable materials and the exciting opportunities for their use in medical devices, as well as discussing our research on the next generation of implantable medical materials and devices.
The session will appeal to anybody with an interest in biomaterials science and engineering including medical device manufacturers. This is a big project and we’re excited to be able to update where we’re up to and what the next steps are,” said Dr Xiang Zhang, Principal Consultant for Lucideon.
Lucideon is currently working on other innovative materials and technologies for this sector, including inorganic controlled release and novel bioceramic materials, including toughened ceramics and ceramic polymer hybrids for bone repair/replacement activities.
“Bioresorbable Materials for Medical Applications” is supported by the ReBioStent project, grant agreement n° 604251 from the European Union’s Seventh Program for research, technological development and demonstration (FP7).